23andMe | 8-K: Current report
23andMe | 8-K: 23andMe Announces CEO's Intention to Pursue a Potential Take-Private
23andMe | 8-K: 23andMe CAO Kathy Hibbs Retires, Guy Chayoun Steps In
23andMe | S-8: Initial registration statement for securities to be offered to employees pursuant to employee benefit plans
23andMe | 8-K: 23andMe Reports Third Quarter Fiscal 2024 Financial Results
23andMe | 8-K: 23andme Announces Fda Clearance of Ind Application for Its Dual Mechanism Antibody, 23me-01473, Targeting Ulbp6
23andMe | 8-K: 23andMe Posted The Investor Presentation
23andMe | 8-K/A: 23andMe Says Some Profiles Were Accessed in Cybersecurity Breach and Has Retained Third-Party Forensic Experts to Assist in an Investigation of the Cause and Scope of the Incident (Amendment)
23andMe | 8-K: Current report
23andMe | 8-K: 23andMe Reports Second Quarter Fiscal 2024 Financial Results
23andMe | 8-K: 23andMe Announces Updated Safety and Preliminary Efficacy Data From the Phase 1/2a Study of 23ME-00610, an Investigational Antibody Targeting CD200R1
23andMe | 8-K: 23andMe Announces Collaboration Extension with a New Data Licensing Agreement with GSK
23andMe | 8-K: Paul Johnson, The Vice President, Europe, And a Named Executive Officer of 23andMe Holding Co., Tendered His Resignation to the Company
23andMe | 8-K: 23andme Says Some Profiles Were Accessed in Cybersecurity Breach and Has Retained Third-Party Forensic Experts to Assist in an Investigation of the Cause and Scope of the Incident
23andMe | 8-K: 23andMe Holding Co. approved the grant of annual long-term equity awards for the fiscal year ending March 31, 2024
23andMe | S-8: Initial registration statement for securities to be offered to employees pursuant to employee benefit plans
23andMe | 8-K: Poll Results of 2023 Stockholders Meeting
23andMe | 8-K: 23andMe Granted New FDA Clearance to Report Additional BRCA Variants
23andMe | 8-K: 23andMe Reports FY2024 First Quarter Financial Results and Reduction in Force and Dr. Kenneth Hillan, Chief Therapeutics Officer of 23andme Holding Co. , Notified the Company of His Decision to Retire
23andMe | DEFR14A: Definitive proxy statement in connection with contested solicitations
No Data